In this paper, we show that Prentice's criteria for surrogates can be strengthened to remedy some weaknesses of the criteria, and we also propose some sufficient conditions under which the treatment effects on a surrogate and on the true endpoint have qualitative implication and equivalence relations. With or without requiring Prentice's criteria, we discuss what conditions are required to qualitatively assess the causal effect of treatment on an unobserved endpoint in terms of an observed surrogate. Rather than a correlation between a surrogate and an endpoint, we require stricter measurements of association for the qualitative assessment. Further we show that these conditions can be satisfied by commonly used models, such as gen...
At the beginning of the 21st century, a new paradigm was introduced for the evaluation of surrogate ...
The individual causal association (ICA) has recently been introduced as a metric of surrogacy in a c...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139917/1/sim7430.pdfhttps://deepblue.l...
When a treatment has a positive average causal effect (ACE) on an intermediate variable or surrogate...
Summary. We define a surrogate end point as a measure or indicator of a biological process that is o...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...
The relationship between association and surrogacy has been the focus of much debate in the surrogat...
Nowadays, two main frameworks for the evaluation of surrogate endpoints, based on causal-inference a...
Several methods have been developed for the evaluation of surrogate endpoints within the causal-infe...
We put a perspective on the strengths and limitations of statistical methods for the evaluation of s...
At the beginning of the 21st century, a new paradigm was introduced for the evaluation of surrogate ...
The individual causal association (ICA) has recently been introduced as a metric of surrogacy in a c...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139917/1/sim7430.pdfhttps://deepblue.l...
When a treatment has a positive average causal effect (ACE) on an intermediate variable or surrogate...
Summary. We define a surrogate end point as a measure or indicator of a biological process that is o...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...
The relationship between association and surrogacy has been the focus of much debate in the surrogat...
Nowadays, two main frameworks for the evaluation of surrogate endpoints, based on causal-inference a...
Several methods have been developed for the evaluation of surrogate endpoints within the causal-infe...
We put a perspective on the strengths and limitations of statistical methods for the evaluation of s...
At the beginning of the 21st century, a new paradigm was introduced for the evaluation of surrogate ...
The individual causal association (ICA) has recently been introduced as a metric of surrogacy in a c...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...